Mesuximide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mesuximide
Mesuximide.svg
Systematic (IUPAC) name
(RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a682028
Pregnancy cat. C (US)
Legal status -only (US)
Routes Oral
Pharmacokinetic data
Metabolism Hepatic (demethylation and glucuronidation)
Half-life 1.4–2.6 hours (mesuximide)
28–38 hours (active metabolite)
Excretion Renal
Identifiers
CAS number 77-41-8 YesY
ATC code N03AD03
PubChem CID 6476
DrugBank DB05246
ChemSpider 6231 YesY
UNII 0G76K8X6C0 YesY
KEGG D00404 YesY
ChEMBL CHEMBL697 YesY
Chemical data
Formula C12H13NO2 
Mol. mass 203.237 g/mol
 N (what is this?)  (verify)

Mesuximide (or methsuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methsuximide is largely due to its pharmacologically active metabolite, N-desmethylmethsuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

References[edit]

  1. ^ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Retrieved August 21, 2006. [dead link]
  2. ^ Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved June 10, 2008. 
  3. ^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.